Reseligo 10,8 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reseligo 10,8 mg

zentiva k.s., Česká republika - goserelín - 44 - cytostatica

Reseligo 3,6 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

reseligo 3,6 mg

zentiva k.s., Česká republika - goserelín - 44 - cytostatica

Xtandi Európska únia - slovenčina - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatické nádory - endokrinná terapia - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Egistrozol Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egistrozol

egis pharmaceuticals plc, maďarsko - anastrozol - 44 - cytostatica

Firmagon Európska únia - slovenčina - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - prostatické nádory - endokrinná terapia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.